INNOCARE Aktie

 

INNOCARE (09969.HK) closed down 4.76% at midday today (24th). The stock once surged in the afternoon session and briefly turned higher by 2.6% to a peak of HKD16.16, but later fell sharply again. It is now trading at HKD14.13, down 10.29%, with trading volume of 18.4012 million shares, involving turnover of HKD274 million.INNOCA......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE (09969.HK) announced that it has entered into a strategic research collaboration and licensing agreement with Eli Lilly and Company (LLY.US) for new drug development.Under the agreement, INNOCARE will leverage its proprietary drug development platform and extensive research experience to develop and advance compounds ta......

InnoCare will receive up to $100 million in upfront and near-term payments, and up to approximately $3.25 billion in milestone payments....

InnoCare Optoelectronics is preparing for a major supply-chain adjustment as Innolux Corporation restructures its factories, with the parent company's second plant scheduled to close in September 2026. President Eric Lee said InnoCare has already built inventory, expanded outsourcing, and lined up a new production line to limit disruption, while also using the transition to strengthen its product mix and expand into semiconductor-related inspection work....

G Sachs issued a research report saying that INNOCARE (09969.HK)'s product sales in the second quarter rose 37% YoY, broadly in line with expectations, benefiting from continued strong growth of its core product orelabrutinib, as well as initial contributions from newly launched tafasitamab (CD19) and Zurletrectinib (pan-TRK).G ......

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

INNOCARE (09969.HK) announced its interim results for the six months ended June 2026. Revenue elevated 55.5% YoY to RMB1.137 billion. The company swung to a profit of RMB246 million, compared with a loss of RMB30.091 million in the corresponding period last year. EPS was RMB0.14. No dividend was declared.Under non-HKFRS measures......

Orelabrutinib in combination with mesutoclax has been granted BTD for the treatment of patients with MZL who have received at least one prior therapy....

In Phase III clinical psoriasis study, InnoCare's novel TYK2i fadeucravacitinib (ICP-488) met the primary endpoint and multiple secondary endpoints....

INNOCARE (09969.HK) announced that fadeucravacitinib (ICP-488), a potent and highly selective tyrosine kinase 2 (TYK2) allosteric inhibitor, successfully met its primary endpoint in a Phase III pivotal clinical trial for the treatment of patients with moderate-to-severe plaque psoriasis.The company said it will continue to compl......

BEIJING, July 16, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Phase II portion of the Phase II/III trial of its TYK2 inhibitor Soficitinib (ICP-332) for non-segmental vitiligo has met the primary endpoint....

INNOCARE (09969.HK) announced that soficitinib (ICP-332), the company's self-developed next-generation oral tyrosine kinase 2 (TYK2) inhibitor, successfully met its primary endpoint in the Phase II portion of an ongoing Phase II/III adaptive clinical study for adult patients with non-segmental vitiligo.Non-segmental vitiligo is ......

BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor soficitinib (ICP-332) met the primary endpoint in patients with moderate-to-severe atopic dermatitis (AD)....

The paper in STTT concludes that orelabrutinib significantly prolongs PFS and reduces the risk of disease progression or death by 68%....

ICP-B208 is InnoCare's second ADC from its in-house platform to enter clinical development. There are no approved CDH17 targeted ADCs globally....

The study showed that orelabrutinib was safe and well tolerated in participants with SLE....

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety....

This is the first NDA acceptance for BTK inhibitor orelabrutinib in autoimmune diseases. No BTK inhibitors have been approved in China for ITP....

INNOCARE (09969.HK) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted the new drug application in China for the Brutons tyrosine kinase (BTK) inhibitor orelabrutinib, indicated for the treatment of patients with primary immune thrombocytopenia (ITP). (sl/a)~AA......